All In Biotech

Drug Trial Radar · NCT06083129

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Nov 28, 2023

Primary completion

Nov 28, 2028

Study completion Nov 28, 2028

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse. This phase III randomised study propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.

Conditions

  • GVHD

Interventions

  • GrafalonDrug

    10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)

  • ThymoglobulinDrug

    2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of grade II-IV acute Graft Versus Host Disease (GVHD) according to the Mount Sinai Acute GVHD International Consortium (MAGIC) classificationTime frame: At day 100 post-transplantation

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Amiens

    Amiens, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • CHU Besançon

    Besançon, France · Recruiting

  • CHU Bordeaux

    Bordeaux, France · Recruiting

  • CHU Brest

    Brest, France · Recruiting

  • CHU Caen

    Caen, France · Recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France · Recruiting

  • Hôpital Henri Mondor AP-HP

    Créteil, France · Not yet recruiting

  • CHU Grenoble

    Grenoble, France · Recruiting

  • CHU Lille

    Lille, France · Recruiting

  • CHU Limoges

    Limoges, France · Recruiting

  • CHU Lyon Sud

    Lyon, France · Recruiting

  • IPC Marseille

    Marseille, France · Recruiting

  • CHU Montpellier

    Montpellier, France · Recruiting

  • CHRU Nancy

    Nancy, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU Nice

    Nice, France · Recruiting

  • Hôpital La Pitié Salpêtrière AP-HP

    Paris, France · Recruiting

  • Hôpital Necker AP-HP

    Paris, France · Recruiting

  • Hôpital Saint Louis AP-HP

    Paris, France · Recruiting

  • Hôpital Saint-Antoine AP-HP

    Paris, France · Recruiting

  • CHU Poitiers

    Poitiers, France · Recruiting

  • CHU Rennes

    Rennes, France · Recruiting

  • CHU Saint Etienne

    Saint-Etienne, France · Recruiting

  • CHRU Strasbourg

    Strasbourg, France · Recruiting

  • Oncopole Toulouse

    Toulouse, France · Recruiting

  • CHRU Tours

    Tours, France · Not yet recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.